To the Editor: We report the use of nebulised frusemide for the symptomatic treatment of end-stage congestive heart failure (CHF). An 84-year-old man with New York Heart Association class IV CHF was referred to the Community Heart Failure Team at St Vincent’s Hospital, Sydney, for ongoing management after a hospital admission for acute pulmonary oedema. His medical history included aortic stenosis, pulmonary hypertension, type 2 diabetes, chronic renal failure, atrial fibrillation, hypertension, chronic obstructive pulmonary disease (COPD) and hypercholesterolaemia.
The full article is accessible to AMA
members and paid subscribers.
Login to MJA or subscribe now.
- 1. Newton PJ, Davidson PM, Macdonald P, et al. Nebulized furosemide for the management of dyspnea: does the evidence support its use? J Pain Symptom Manage 2008; 36: 424-441.
Online responses are no longer available. Please refer to our instructions for authors page for more information.
We thank Professor Patricia Davidson and Dr Phillip Newton of the Centre for Cardiovascular and Chronic Care, Curtin University, Sydney, NSW, for their assistance.